These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25712457)

  • 1. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL).
    Chihara D; Asano N; Ohmachi K; Nishikori M; Okamoto M; Sawa M; Sakai R; Okoshi Y; Tsukamoto N; Yakushijin Y; Nakamura S; Kinoshita T; Ogura M; Suzuki R
    Ann Oncol; 2015 May; 26(5):966-973. PubMed ID: 25712457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of central nervous system relapse in mantle cell lymphoma.
    Conconi A; Franceschetti S; Lobetti-Bodoni C; Stathis A; Margiotta-Casaluci G; Ramponi A; Mazzucchelli L; Bertoni F; Ghielmini M; Gaidano G; Cavalli F; Zucca E
    Leuk Lymphoma; 2013 Sep; 54(9):1908-14. PubMed ID: 23339449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.
    Kim DH; Medeiros LJ; Aung PP; Young KH; Miranda RN; Ok CY
    Am J Surg Pathol; 2019 Oct; 43(10):1421-1428. PubMed ID: 31219818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.
    Cheah CY; George A; Giné E; Chiappella A; Kluin-Nelemans HC; Jurczak W; Krawczyk K; Mocikova H; Klener P; Salek D; Walewski J; Szymczyk M; Smolej L; Auer RL; Ritchie DS; Arcaini L; Williams ME; Dreyling M; Seymour JF;
    Ann Oncol; 2013 Aug; 24(8):2119-23. PubMed ID: 23616279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
    Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
    Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
    Gill S; Herbert KE; Prince HM; Wolf MM; Wirth A; Ryan G; Carney DA; Ritchie DS; Davies JM; Seymour JF
    Br J Haematol; 2009 Oct; 147(1):83-8. PubMed ID: 19694718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
    Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
    Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central nervous system involvement by mantle cell lymphoma.
    McLaughlin N; Wang Y; Witzig T; Villasboas J; Habermann T; Inwards D; Bennani N; Thanarajasingam G; Nowakowski G; Porrata L; Thompson C; Micallef I; Johnston P; Ansell S; Paludo J
    Leuk Lymphoma; 2023 Feb; 64(2):371-377. PubMed ID: 36416595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system involvement in mantle cell lymphoma.
    Ferrer A; Bosch F; Villamor N; Rozman M; Graus F; Gutiérrez G; Mercadal S; Campo E; Rozman C; López-Guillermo A; Montserrat E
    Ann Oncol; 2008 Jan; 19(1):135-41. PubMed ID: 17962207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
    Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
    Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
    He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
    Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma.
    Räty R; Franssila K; Joensuu H; Teerenhovi L; Elonen E
    Eur J Haematol; 2002 Jul; 69(1):11-20. PubMed ID: 12270057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting.
    Ladetto M; Sametti S; Astolfi M; Corradini P; Ricca I; Drandi D; Pileri A; Tarella C
    Leuk Lymphoma; 2001 Feb; 40(5-6):679-82. PubMed ID: 11426542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
    Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
    Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.